Ardelyx, Inc. Form 4 Filings

ARDELYX, INC. (ARDX) reported that Senior Vice President and Chief Accounting Officer Joseph James Reilly sold a total of 3,982 shares of common stock on August 21, 2026. According to the disclosure, these sales were an automatic sell-to-cover triggered by the vesting of restricted stock units and were executed solely to cover applicable withholding taxes, at a weighted average price of $3.8569 per share across multiple trades.

ARDELYX, INC. (ARDX) reported that Chief Technical and Quality Officer John E. Bishop sold a total of 19,750 shares of common stock on 2026-08-21 at a weighted average price of $3.8569 per share. According to the company’s disclosure, these shares were sold pursuant to an automatic sell-to-cover feature triggered by the vesting of restricted stock units, and were disposed of solely to cover applicable withholding taxes.

Ardelyx, Inc. (ARDX) reported that Chief Human Resources Officer Brady James Parker sold a total of 15,136 shares of common stock on August 21, 2026. According to the company’s disclosure, these sales were an automatic sell-to-cover related to vesting RSUs, executed solely to cover withholding taxes at a weighted average price of $3.8569 per share across multiple trades.

ARDELYX, INC. (ARDX) reported that Chief Commercial Officer Eric Duane Foster sold a total of 8,562 shares of common stock on 2026-08-21 at a weighted average price of $3.8569 per share. According to the footnote, these sales were an automatic sell-to-cover triggered upon vesting of restricted stock units and were made solely to cover applicable withholding taxes, executed in multiple trades between $3.648 and $3.984 per share.

ARDELYX, INC. (ARDX) reported that Chief Business Officer Mike Kelliher sold a total of 7,758 shares of common stock on 2026-08-21. The sales were executed as an automatic sell-to-cover required by the terms of his restricted stock unit awards, and were made solely to cover applicable withholding taxes upon RSU vesting. The transactions occurred in multiple trades at prices ranging from $3.648 to $3.984 per share, with a weighted average sale price of $3.8569 per share.

ARDELYX, INC. (ARDX) reported that Chief Patient Officer Laura A. Williams sold common stock in multiple transactions on August 21, 2026. A total of 10,739 shares of common stock were sold at a weighted average price of $3.8569 per share, with individual trade prices ranging from $3.648 to $3.984 per share. According to the RSU grant terms, these were automatic sell-to-cover transactions executed upon vesting of restricted stock units, conducted solely to cover applicable withholding taxes.

ARDELYX, INC. (ARDX) reported that President & CEO Michael Raab sold a total of 58,574 shares of common stock on 2026-08-21 in four open-market transactions. According to the disclosure, these sales were an automatic sell-to-cover upon vesting of RSU awards, executed solely to cover withholding taxes, at a weighted average price of $3.8569 per share across trades ranging from $3.648 to $3.984. Raab also has indirect ownership through a living trust and trusts for his children, as noted in the filing, though this entry does not state the share counts for those holdings.

Ardelyx, Inc. President & CEO Michael Raab reported several stock transactions. On July 15, 2026 he sold 41,668 common shares at a weighted average of $5.062 per share, in trades ranging from $5.03 to $5.12, under a Rule 10b5-1 trading plan adopted on November 7, 2025. He also exercised stock options for 20,834 shares at an exercise price of $0.99 per share, leaving 1,720,034 directly held common shares, trust holdings of 24,364 shares in the Michael G. Raab Living Trust and 1,000 shares in trusts for his children, and 290,834 remaining stock options at a $0.99 exercise price expiring January 6, 2032.

Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an open-market sale of 81,898 shares of common stock at a weighted average price of $5.989 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026, and the trades occurred in a price range from $5.97 to $6.0086. Following the sale, Williams directly holds 378,195 shares of Ardelyx common stock. On the same date, she also exercised a stock option to acquire 31,000 shares at an exercise price of $0.99 per share, reducing the outstanding option grant tied to those shares.

ARDELYX, INC. director Merdad Parsey reported equity compensation awards rather than open-market trades. He received 26,455 restricted stock units, each convertible into one share of common stock upon vesting, granted under the company’s Non-Employee Director Compensation Program.

He was also granted an option for 39,715 shares of common stock at an exercise price of $5.67 per share, expiring in 2036. The option vests in equal monthly installments over 12 months, with any unvested portion vesting in full at the next annual stockholder meeting, subject to continued service. Following these awards, he directly holds 83,746 shares of common stock.

ARDELYX director Richard J. Rodgers received new equity awards as part of the Non-Employee Director Compensation Program. He acquired 26,455 restricted stock units and a stock option for 39,715 shares at $5.67 per share, bringing his direct holdings to 439,998 common shares.

The RSUs convert into one share each upon vesting. The option vests monthly over 12 months and any unvested portion accelerates at the next annual stockholder meeting, subject to his continued service.

ARDELYX, INC. director David M. Mott reported equity awards under the company’s Non-Employee Director Compensation Program. He received two grants of Common Stock totaling 46,737 shares at no cash cost and a stock option for 39,715 shares at an exercise price of $5.67 per share, expiring on June 16, 2036. Footnotes explain that some shares are held for entities associated with New Enterprise Associates and that restricted stock units and the option vest over time, with acceleration tied to the next annual stockholders’ meeting.

ARDELYX, INC. director Onaiza Cadoret-Manier received equity compensation on June 16, 2026. She was granted 26,455 restricted stock units, each convertible into one share of common stock under the Non-Employee Director Compensation Program, bringing her direct holdings to 178,156 common shares. She also received a stock option for 39,715 shares of common stock at an exercise price of $5.67 per share, expiring on June 16, 2036. The option vests in equal monthly installments over 12 months and any unvested portion accelerates at the next annual stockholders’ meeting, subject to continued service.

Ardelyx, Inc. director Muna Bhanji reported compensation-related equity grants. She received 26,455 restricted stock units, each convertible into one share of common stock upon vesting, under the company’s Non-Employee Director Compensation Program.

She was also granted options on 39,715 shares at an exercise price of $5.6700 per share, expiring on June 16, 2036. These options vest in 12 equal monthly installments and any remaining unvested portion will fully vest on the date of the next annual stockholders’ meeting, subject to continued service. Following these awards, she directly holds 163,808 shares of common stock.

Ardelyx director William C. Bertrand Jr. reported equity-based compensation grants. On June 16, 2026, he received 26,455 shares of common stock issued under Ardelyx’s Non-Employee Director Compensation Program after electing to take stock instead of cash fees.

He was also granted restricted stock units that convert into one share of common stock per unit upon vesting, issued under the same director program. In addition, he received a stock option for 39,715 shares at an exercise price of $5.67 per share, expiring June 16, 2036, which vests monthly with potential accelerated vesting at the next annual stockholders’ meeting.

ARDELYX, INC. director Robert B. Bazemore received equity compensation consisting of both shares and options. He was granted 26,455 restricted stock units, each convertible into one share of common stock upon vesting under the Non-Employee Director Compensation Program, bringing his direct holdings to 68,006 shares. He also received a stock option for 39,715 shares at an exercise price of $5.67 per share, vesting in 12 monthly installments and expiring on June 16, 2036, with unvested portions accelerating at the next annual stockholders’ meeting if he continues in service.

ARDELYX, INC. President & CEO Michael Raab reported mixed equity activity in company stock. He sold 41,666 shares of common stock on June 15, 2026 at a weighted average price of $5.6724 per share in an open-market transaction made under a Rule 10b5-1 trading plan adopted on November 7, 2025. On the same date, he exercised stock options to acquire 20,833 common shares at an exercise price of $0.99 per share. Following these transactions, he holds 1,699,200 shares of common stock directly, along with additional indirect holdings of 1,000 and 24,364 shares through family trusts, and 311,668 stock options remaining outstanding.

ARDELYX, INC. officer Joseph James Reilly reported selling a total of 3,719 shares of common stock at an average price of $6.2675 per share. According to the footnotes, these sales were automatic sell-to-cover transactions triggered by the vesting of restricted stock units and were made solely to cover withholding taxes. After the sales, he directly holds 149,107 shares of Ardelyx common stock. The holdings include 1,765 shares acquired under the company’s employee stock purchase plan on February 27, 2026.

Ardelyx, Inc. Chief Financial Officer Susan Hohenleitner reported a small tax-related share sale. She disposed of 1,455 shares of common stock on May 21, 2026 at an average price of $6.2675 per share. A footnote explains the transaction was an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes rather than as a discretionary open-market sale. After this transaction, she directly holds 229,078 Ardelyx common shares.

ARDELYX, INC. officer John E. Bishop reported a small sale of common stock tied to restricted stock unit (RSU) vesting. He disposed of 2,306 shares at an average price of $6.2675 per share, and held 336,845 shares afterward.

According to the footnote, the transaction was an automatic sell-to-cover required by the original RSU grant terms, with shares sold solely to pay applicable withholding taxes. This indicates a routine, compensation-related tax event rather than a discretionary open-market sale based on a view of the stock.

ARDELYX, INC. reported that Chief Human Resources Officer Brady James Parker had 1,846 shares of common stock sold at an average price of $6.2675 per share. According to the footnote, this automatic sell-to-cover transaction occurred upon RSU vesting to satisfy withholding taxes, leaving him with 261,066 shares directly owned.

ARDELYX, INC. Chief Commercial Officer Eric Duane Foster reported sales of 7,998 shares of common stock on May 21, 2026 at a price of $6.2675 per share.

According to the footnote, these trades were an automatic sell-to-cover tied to vested restricted stock units and were executed solely to cover applicable withholding taxes rather than as discretionary open-market sales.

ARDELYX, INC. Chief Business Officer Mike Kelliher reported selling a total of 7,248 shares of common stock on May 21, 2026 at a price of $6.2675 per share in three separate transactions. A footnote explains these sales were an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes. This indicates the activity was a tax-related mechanism tied to equity compensation rather than a discretionary reduction of his investment in the company.

Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported multiple open-market sales totaling 6,989 shares of common stock at $6.2675 per share. According to the footnote, these transactions were automatic sell-to-cover trades tied to RSU vesting, executed solely to pay withholding taxes. Williams continued to hold 429,093 shares directly after the transactions.

ARDELYX, INC. President & CEO Michael Raab reported routine sales of company common stock tied to restricted stock unit (RSU) vesting. On May 21, 2026, entities associated with him sold a total of 54,748 shares of Ardelyx common stock at $6.2675 per share.

According to the disclosure, these transactions were an automatic sell-to-cover required by the original RSU grant terms, and the shares were sold solely to cover applicable withholding taxes at vesting. After these sales, Raab directly held about 1,759,848 common shares, with additional indirect holdings of 1,000 shares and 24,364 shares held in family-related trusts.

ARDELYX, INC. President & CEO Michael Raab reported an open-market sale and an option exercise involving the company’s common stock. He sold 41,666 shares on May 15, 2026 at a weighted average price of $6.2788 per share under a pre-arranged Rule 10b5-1 trading plan.

On the same date he exercised 20,833 stock options at a strike price of $0.99 per share, receiving the underlying common shares. After these transactions he held 1,814,447 shares of common stock directly and 332,501 stock options, plus indirect holdings of 1,000 and 24,364 shares through family trusts.

ARDELYX, INC. President & CEO Michael Raab exercised stock options and sold shares in a planned transaction. He exercised options for 20,834 shares of common stock at an exercise price of $0.99 per share, then sold 41,668 common shares at a weighted average price of $6.2867 per share pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he holds 1,795,614 shares directly, plus additional indirect holdings of 24,364 and 1,000 shares held in family trusts.

ARDELYX, INC. President & CEO Michael Raab exercised stock options to acquire 20,833 shares of common stock at $0.99 per share, then sold 41,666 shares at a weighted average price of $5.84 per share under a pre-arranged Rule 10b5-1 trading plan.

After these transactions, he held 1,816,448 common shares directly and 374,168 stock options of this award, plus indirect holdings of 24,364 and 1,000 shares through family trusts for his children.

ARDELYX, INC. President & CEO Michael Raab reported option exercises and share sales in ARDX. He exercised stock options for 20,833 shares of common stock at an exercise price of $0.99 per share through a derivative conversion. The resulting 20,833 common shares were acquired and then partially offset by an open-market sale of 41,666 common shares at a weighted average price of $6.255 per share, executed in multiple trades between $6.08 and $6.56. The sale was made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, Raab directly held 1,836,153 common shares, with additional shares held indirectly through family trusts for his children.

Ardelyx director David M. Mott reported an open-market purchase of 333,333 shares of Ardelyx common stock. The weighted average purchase price was $5.839 per share, with individual trades executed between $5.67 and $6.00 per share. Following this transaction, he reports ownership of 3,302,918 shares, which includes 87,566 shares he holds for the benefit of entities associated with New Enterprise Associates, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

ARDELYX, INC. officer John E. Bishop reported automatic sales of company common stock tied to the vesting of restricted stock units. On February 20, 2026, a total of 3,179 shares of common stock were sold in several open-market transactions at prices between $5.70 and $5.87 per share. According to the footnote, these were automatic “sell-to-cover” transactions executed solely to cover withholding taxes due upon RSU vesting, rather than discretionary sales. After these tax-related sales, Bishop directly held 339,151 shares of Ardelyx common stock.

ARDELYX, INC. executive Joseph James Reilly reported open-market sales of 4,991 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these transactions were automatic sell-to-cover trades upon RSU vesting, executed solely to cover withholding taxes. After the sales, Reilly directly owned 151,790 Ardelyx shares.

ARDELYX, INC. executive Laura A. Williams reported automatic sales of company common stock tied to restricted stock unit (RSU) vesting. On February 20, 2026, she sold 7,192 shares at $5.865 and 984 shares at $5.7138 in open-market transactions. A footnote explains these were “sell-to-cover” transactions required by the RSU grant terms to cover withholding taxes upon vesting, rather than discretionary sales. Following these sales, she continued to hold over four hundred thousand Ardelyx shares directly.

ARDELYX, INC. Chief Financial Officer Susan Hohenleitner reported an automatic tax-related sale of company stock. On February 20, 2026, she sold a total of 2,033 shares of common stock in open-market transactions, at prices of $5.865 and $5.7138 per share. According to a footnote, these sales were an automatic sell-to-cover triggered by vesting restricted stock units and were made solely to cover withholding taxes. After these transactions, she directly owned 230,533 shares of Ardelyx common stock.

Ardelyx, Inc. executive Brady James Parker, the Chief Human Resources Officer, reported selling a total of 2,543 shares of common stock on February 20, 2026 in open-market transactions at prices of $5.865 and $5.7138 per share.

According to the footnote, these sales were an automatic sell-to-cover triggered upon the vesting of restricted stock units and were executed solely to cover applicable withholding taxes. After the transactions, Parker directly owned 262,912 Ardelyx shares.

Ardelyx, Inc. officer Mike Kelliher reported automatic sales of company common stock tied to vested restricted stock units. On February 20, 2026, he sold a total of 9,595 shares in open-market transactions at prices around $5.71–$5.87 per share.

According to the footnote, these were “automatic sell-to-cover” transactions required under the original RSU grant terms and were executed solely to cover withholding taxes, rather than discretionary sales. After these transactions, Kelliher directly holds 364,666 shares of Ardelyx common stock.

ARDELYX, INC. President & CEO Michael Raab reported open-market sales of a total of 45,982 shares of common stock on February 20, 2026, at prices around $5.70 to $5.87 per share. According to the filing, these sales were executed pursuant to an automatic sell-to-cover feature tied to restricted stock unit vesting and were made solely to cover applicable withholding taxes.

After these transactions, Raab directly holds 1,856,988 shares as trustee of the Michael G. Raab Living Trust dated July 25, 2012, and also has indirect ownership of 24,364 and 1,000 shares through trusts established for his children.

Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported open-market sales of a total of 10,439 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these trades were executed automatically to sell shares upon restricted stock unit vesting solely to cover withholding taxes. After these transactions, he directly owned 425,970 Ardelyx common shares.

Ardelyx, Inc. reported that Senior Vice President of Finance Joseph James Reilly received new equity awards on January 23, 2026. He was granted 46,200 restricted stock units (RSUs), which each convert into one share of common stock upon vesting, at a grant price of $0. He also received a stock option for 69,360 shares of common stock at an exercise price of $7.77 per share, with the option vesting in 48 equal monthly installments starting January 23, 2026, conditioned on continued service. Following these awards, he beneficially owns 156,781 shares of Ardelyx common stock, which includes 1,667 shares acquired through the company’s employee stock purchase plan on August 31, 2025.

Ardelyx, Inc. reported that Chief Business Officer Mike Kelliher received new equity awards on January 23, 2026. He was granted 103,080 restricted stock units, each convertible into one share of common stock upon vesting. He also received a stock option for 154,625 shares of common stock at an exercise price of $7.77 per share, vesting in 48 equal monthly installments starting January 23, 2026, subject to continued service. Following these awards, he directly beneficially owned 374,261 shares of Ardelyx common stock.

Ardelyx, Inc. chief financial officer Susan Hohenleitner reported equity awards consisting of common stock and stock options. On January 23, 2026, she received 85,670 shares of common stock at a price of $0, described as restricted stock units that convert into one share of common stock per unit upon vesting. Following this grant, she beneficially owned 232,566 shares of Ardelyx common stock directly.

On the same date, she was also granted a stock option for 128,505 shares with an exercise price of $7.77 per share and an expiration date of January 23, 2036. The option becomes exercisable as it vests in 48 equal monthly installments starting on January 23, 2026, conditioned on her continued employment or service with Ardelyx.

Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported new equity awards and updated his share holdings. On January 23, 2026, he received 137,945 shares of Common Stock for no cash consideration in the form of restricted stock units, each RSU converting into one share upon vesting. Following this grant, he beneficially owned 436,409 shares of Common Stock, which include 2,780 shares previously purchased under the Ardelyx Employee Stock Purchase Plan on August 31, 2025. He was also granted a stock option for 206,915 shares of Common Stock with a $7.77 exercise price, vesting in 48 equal monthly installments beginning on January 23, 2026, contingent on his continued employment.

Ardelyx, Inc. President and CEO Michael Raab reported new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he received 446,220 RSUs at a price of $0, each RSU convertible into one share of common stock upon vesting. On the same date, he was granted a stock option for 669,330 shares of common stock at an exercise price of $7.77 per share, which vests in 48 equal monthly installments starting January 23, 2026, subject to continued service. Following these grants, Raab directly holds 1,902,968 shares of Ardelyx common stock, with additional indirect holdings of 24,364 shares and 1,000 shares through family trusts.

Ardelyx, Inc. reported an equity compensation grant to its Chief Human Resources Officer effective January 23, 2026. The officer received 99,455 restricted stock units (RSUs), with each RSU settling into one share of common stock upon vesting, increasing the officer’s directly held common stock to 265,455 shares. On the same date, the officer was also granted a stock option for 149,185 shares of common stock at an exercise price of $7.77 per share. The option vests in 48 equal monthly installments starting from January 23, 2026, conditioned on continued employment or service, and will remain exercisable until January 23, 2036.

Ardelyx Chief Patient Officer receives new equity awards. Laura A. Williams reported a grant of 82,695 shares of Ardelyx common stock on January 23, 2026, issued at $0 per share as restricted stock units that convert 1-for-1 into common stock when they vest. She also received a stock option for 124,040 shares of common stock at an exercise price of $7.77 per share, granted at no cost. The option vests in 48 equal monthly installments starting January 23, 2026, conditioned on her continued employment or service. Following these transactions, Williams directly beneficially owned 444,258 shares of Ardelyx common stock.

Ardelyx, Inc. reported an equity award to executive John E. Bishop, its Chief Technical and Quality Officer. On January 23, 2026, he received 124,330 shares of Common Stock in the form of restricted stock units, at a price of $0 per share, bringing his directly held Common Stock to 342,330 shares after the grant. He was also granted a stock option for 186,500 shares of Common Stock with an exercise price of $7.77 per share. The option vests in 48 equal monthly installments beginning on January 23, 2026, subject to his continued employment or service, and is exercisable through January 23, 2036.

Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an option exercise and share sale in Ardelyx common stock. On January 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $0.99 per share, then sold 50,000 shares at a weighted average price of $6.978 per share, with individual trades executed between $6.97 and $7.00.

After these transactions, Williams directly owned 361,563 shares of Ardelyx common stock, a figure that reflects an earlier purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025. She also held 62,000 stock options with a $0.99 exercise price, expiring on January 6, 2032, which vest in equal monthly installments that began in January 2022.

Ardelyx, Inc. (ARDX) insider activity: Chief Legal and Administrative Officer Elizabeth Grammer reported a Form 4 transaction dated 11/21/2025. She sold 5,995 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, and the shares were sold solely to cover applicable withholding taxes.

After this transaction, she beneficially owns 299,895 shares of Ardelyx common stock directly.

Ardelyx, Inc. (ARDX) reported an insider stock sale by its president and CEO, who is also a director. On 11/21/2025, the executive sold 46,887 shares of common stock at $5.5369 per share. According to the filing, this sale was made under an automatic sell-to-cover feature tied to restricted stock unit (RSU) awards and was done solely to cover withholding taxes due at vesting.

After this transaction, the executive beneficially owns 1,455,363 shares of Ardelyx common stock directly. In addition, 24,364 shares are held in a living trust and 1,000 shares are held in trusts for the executive’s children, both reported as indirect ownership.